An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects is a PHASE1 clinical asset sponsored by Hoffmann-La Roche in Healthy Volunteers. SEO and diligence focus: Risdiplam, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.